Abu Rous Fawzi, Li Pin, Carskadon Shannon, Singh Sunny Rk, Chacko Rebecca, Abushukair Hassan, Gadgeel Shirish, Palanisamy Nallasivam
Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Health, Detroit, Michigan.
Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan.
JTO Clin Res Rep. 2023 Feb 28;4(4):100486. doi: 10.1016/j.jtocrr.2023.100486. eCollection 2023 Apr.
Amplification of 3q is the most common genetic alteration identified in squamous cell carcinoma of the lung (LUSC), with the most frequent amplified region being 3q26 to 3q28.
In this analysis, we aim to describe the prognostic relevance of 3q amplification by focusing on a minimal common region (MCR) of amplification constituted of 25 genes. We analyzed 511 cases of LUSC from The Cancer Genome Atlas and included 476 in the final analysis.
We identified a 25-gene MCR that was amplified in 221 (44.3%) cases and was associated with better disease-specific survival (not reported [NR] versus 9.25 y, 95% confidence interval [CI]: 5.24-NR, log-rank = 0.011) and a progression-free interval of 8 years (95% CI: 5.1-NR) versus 4.9 years (95% CI: 3.5-NR, log-rank = 0.020). Multivariable analysis revealed that MCR amplification was associated with improved disease-specific survival and progression-free interval.
Amplification of the 25-gene MCR within 3q was present in 44% of this cohort, consisting mainly of Caucasian patients with early stage LUSC. This analysis strongly indicates the prognostic relevance of the 25-gene MCR within 3q. We are further evaluating its prognostic and predictive relevance in a racially diverse patient population with advanced LUSC.
3q扩增是肺鳞状细胞癌(LUSC)中最常见的基因改变,最常见的扩增区域为3q26至3q28。
在本分析中,我们旨在通过聚焦由25个基因构成的最小共同扩增区域(MCR)来描述3q扩增的预后相关性。我们分析了来自癌症基因组图谱的511例LUSC病例,最终分析纳入476例。
我们鉴定出一个25基因的MCR,在221例(44.3%)病例中发生扩增,且与更好的疾病特异性生存相关(未报告[NR]对比9.25年,95%置信区间[CI]:5.24 - NR,对数秩检验 = 0.011),无进展生存期为8年(95% CI:5.1 - NR)对比4.9年(95% CI:3.5 - NR,对数秩检验 = 0.020)。多变量分析显示MCR扩增与改善的疾病特异性生存和无进展生存期相关。
该队列中44%的患者存在3q内25基因MCR的扩增,主要由早期LUSC的白种人患者组成。该分析强烈表明3q内25基因MCR的预后相关性。我们正在进一步评估其在晚期LUSC的种族多样化患者群体中的预后和预测相关性。